OLMESARTAN MEDOXOMIL / HYDROCHLOROTHIAZIDE TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

זמין מ:

JUBILANT GENERICS LIMITED

קוד ATC:

C09DA08

INN (שם בינלאומי):

OLMESARTAN MEDOXOMIL AND DIURETICS

כמות:

12.5MG; 40MG

טופס פרצבטיות:

TABLET

הרכב:

HYDROCHLOROTHIAZIDE 12.5MG; OLMESARTAN MEDOXOMIL 40MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

30/100/1000

סוג מרשם:

Prescription

איזור תרפויטי:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

leaflet_short:

Active ingredient group (AIG) number: 0252502002; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2017-05-01

מאפייני מוצר

_Pr_
_Olmesartan Medoxomil / Hydrochlorothiazide_
Page 1 of 34
PRODUCT MONOGRAPH
PR
OLMESARTAN MEDOXOMIL / HYDROCHLOROTHIAZIDE
Olmesartan Medoxomil and Hydrochlorothiazide Tablets
20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg
Angiotensin II AT
1
Receptor Blocker - Diuretic
MANUFACTURER: Date of Revision: March 13, 2020
Jubilant Generics Limited
1-A, Sector -16A, Institutional Area,
Noida -201301, Uttar Pradesh, India
IMPORTER AND DISTRIBUTOR:
JAMP Pharma Corporation,
1310 rue Nobel, Boucherville,
QC, Canada, J4B 5H3
CONTROL NO: 236598
_Pr_
_Olmesartan Medoxomil / Hydrochlorothiazide_
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................3
SUMMARY PRODUCT
INFORMATION.......................................................................................3
INDICATIONS AND CLINICAL USE
............................................................................................3
CONTRAINDICATIONS
..................................................................................................................3
WARNINGS AND PRECAUTIONS
................................................................................................4
ADVERSE REACTIONS
..................................................................................................................9
DRUG INTERACTIONS
...............................................................................................................12
DOSAGE AND ADMINISTRATION
...........................................................................................16
OVERDOSAGE
..............................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
..........................................................................19
STORAGE AND STABILITY
.......................................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................